Loading clinical trials...
Loading clinical trials...
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions
Interventions
Vemurafenib
Bevacizumab
+1 more
Locations
14
United States
The Angeles Clinic
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Washington Cancer Institute at MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
August 1, 2013
Primary Completion Date
January 1, 2016
Completion Date
June 1, 2016
Last Updated
October 24, 2017
NCT07177937
NCT02621021
NCT03050268
NCT05969860
NCT03340506
NCT04693377
Lead Sponsor
Melanoma Research Foundation Breakthrough Consortium
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions